Journal of Managed Care & Specialty Pharmacy

Article	Citations
“It’s Time to Represent”: shifting the paradigm to improve the quality of inputs into value assessment frameworks	26
Commercial health plans use of patient subgroup restrictions: An analysis of orphan and US Food and Drug Administration–expedited programs	26
Factors associated with primary nonadherence to newly initiated direct oral anticoagulants in patients with nonvalvular atrial fibrillation	20
Emerging trends in public policy: Perspectives on the 2024 AMCP Foundation Survey	19
Real-world calibration and transportability of the Disease Recovery Evaluation and Modification (DREaM) randomized clinical trial in adult Medicaid beneficiaries with recent-onset schizophrenia	16
Effect of the population health inpatient Medicare Advantage pharmacist intervention on hospital readmissions: A quasi-experimental controlled study	16
Getting to specialty treatment in dermatologic inflammatory conditions: Treatment requirements and patient journey	16
Impact of continuous glucose monitoring on emergency department visits and all-cause hospitalization rates among Medicaid beneficiaries with type 2 diabetes treated with multiple daily insulin or basa	14
Innovation is the driver behind quality improvements in diabetes care delivery	12
Call for the alignment of Medicare Part D formularies with clinical treatment guidelines for asthma	12
Real-world treatment and health care utilization among patients with Duchenne muscular dystrophy by race and ethnicity in a Medicaid population	11
Health care resource utilization and costs in patients receiving long-acting injectable vs oral antipsychotics: A comparative analysis from the Disease Recovery Evaluation and Modification (DREaM) stu	10
Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 3	10
Complement activation products vs standard ANA testing: Treatment outcomes, diagnosis, and economic impact (CAPSTONE) in systemic lupus erythematosus	10
Examining US commercial health plans’ use of The Institute for Clinical and Economic Review’s reports in specialty drug coverage decisions	10
Racial and ethnic disparities due to Medicare Part D Star Ratings criteria among kidney transplant patients with diabetes, hypertension, and/or dyslipidemia	10
Prescription digital therapeutics: Applying Medicaid experience to value assessment and formulary management	10
Clinical and economic impact of primary hyperoxaluria: a retrospective claims analysis	10
Emerging trends in information technology: Perspectives on the 2024 AMCP Foundation Survey	10
Oral treatments for outpatient COVID-19: Effectiveness and value	9
Specialty drug and health care utilization vary by wage level in employer-sponsored health plans	9
Cardiovascular risk prediction model and stratification in patients with type 2 diabetes enrolled in a Medicare Advantage plan	9
Poster Abstracts - Academy of Managed Care Pharmacy 2023	9
Comparative effectiveness of pegfilgrastim biosimilars vs originator for prevention of febrile neutropenia: A retrospective cohort study	9
Cost sharing: implications of a well-intended benefits strategy	9

Advancing a managed care pharmacy research agenda: Generating real-world evidence to support US Food and Drug Administration Accelerated Approvals and improving benefit design to address health inequi	9
What is needed to sustain comprehensive medication management? One health plan’s perspectives	8
Direct-acting antiviral retreatment patterns for hepatitis C	8
Reducing disparities in medication use: Responding to managed care pharmacy’s imperatives	8
A decade of increases in Medicare Part B pharmaceutical spending: what are the drivers?	8
Effect of relaxing hepatitis C treatment restrictions on direct-acting antiviral use in a Medicaid program: an interrupted time series analysis	8
FDA expedited approval and implications for rational formulary and health plan design	7
Payer perceptions on the use of economic models in oncology decision making	7
Understanding differences between what alternate propensity score methods estimate	7
RESPONSE TO: COST-SHARING: IMPLICATIONS OF A WELL-INTENDED BENEFITS STRATEGY	7
The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non–small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations	7
International reference pricing of pharmaceuticals in the United States: Implications for potentially curative treatments	7
Pharmacists as clinical care partners: How a pharmacist-led intervention is associated with improved medication adherence in older adults with common chronic conditions	6
Economic burden of peanut allergy in pediatric patients with evidence of reactions to peanuts in the United States	6
Primary care provider payment models and adherence to anticoagulation in patients with atrial fibrillation	6
Impact of the COVID-19 pandemic on hepatitis C outcomes at a health-system specialty pharmacy	6
Prevalence, incidence, and treatment patterns of fistulizing Crohn disease: A US population-based cohort study	6
Striving for Affordable Medicine: Lessons in Price Negotiation Learned from the United Kingdom	6
Building health plan–pharmacist provider partnerships to optimize medication outcomes	6
Incidence and economic burden of respiratory syncytial virus among adults in the United States: A retrospective analysis using 2 insurance claims databases	6
The effectiveness and value of midomafetamine-assisted psychotherapy for posttraumatic stress disorder	6
Economic and utilization outcomes of medication management at a large Medicaid plan with disease management pharmacists using a novel artificial intelligence platform from 2018 to 2019: a retrospectiv	6
Analyzing the use and impact of elexacaftor/tezacaftor/ivacaftor on total cost of care and other health care resource utilization in a commercially insured population	6
Comparison of time to treatment initiation of specialty medications between an integrated health system specialty pharmacy and external specialty pharmacies	6
Patient liability, treatment adherence, and treatment persistence associated with state bans of copay accumulator adjustment programs	6
A real-world study of persistence and adherence to prescription medications in patients with chronic idiopathic constipation in the United States	6
Specialty drug use for autoimmune conditions varies by race and wage among employees with employer-sponsored health insurance	6
Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: a retrospective observational study	6
Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: evidence from a managed care database in the United States	5
Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapy	5
Productivity loss by cancer stage in patients newly diagnosed with hepatocellular carcinoma: A claims database analysis	5
The implementation of value-based frameworks, clinical care pathways, and alternative payment models for cancer care in the United States	5
Comparison of real-world clinical and economic outcomes in patients receiving oral anticoagulants: A retrospective claims analysis	5
Cost-effectiveness of large-panel next-generation sequencing in guiding first-line treatment decisions for patients with nonsquamous advanced non–small cell lung cancer	5
Evaluation of financial outcomes under a value-based payment program for community pharmacies	5
Increased health care costs associated with new persistent opioid use after major surgery in opioid-naive patients	5
Sustaining competition for biosimilars on the pharmacy benefit: Use it or lose it	5
Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist	5
Optimizing the management of inherited blood disorders in a changing market: Findings from the AMCP Market Insights Program	5
Characterizing demographics, comorbidities, and costs of care among populations with Duchenne muscular dystrophy with Medicaid and commercial coverage	5
COVID-19 and adherence to biologic therapies for psoriasis: An analysis of nationwide pharmacy claims data	5
Real-world outcomes among patients with HER2+ metastatic breast cancer with brain metastases	5
Treatment utilization patterns of newly initiated oral anticancer agents in a national sample of Medicare beneficiaries	5
Medication and bone health in multiple sclerosis: A systematic review and meta-analysis	5
Racial and social inequities in medication use: A review of articles responding to the Journal of Managed Care + Specialty Pharmacy’s Call to Action	5
Medicare drug price negotiation: The complexities of selecting therapeutic alternatives for estimating comparative effectiveness	4
Characteristics of adverse event reporting of Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to the US Food and Drug Administration	4
Addressing racial inequality and its effects on vaccination rate: A trial comparing a pharmacist and peer educational program (MOTIVATE) in diverse older adults	4
Uptake and cost of biosimilar filgrastim among Medicare and Medicaid populations in 2015-2018	4
The cost-effectiveness of brigatinib in adult patients with ALK inhibitor–naive ALK-positive non–small cell lung cancer from a US perspective	4

Impact of formulary-related pharmacy claim rejections of cariprazine on health care utilization and treatment patterns among patients with bipolar I disorder	4
Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes	4
Correction	4
Comparative value of dapagliflozin vs empagliflozin in patients with heart failure and preserved ejection fraction: A cost-effectiveness analysis	4
Real-world opioid use among patients with migraine enrolled in US commercial insurance and risk factors associated with migraine progression	4
The effect of unobserved preferences and race on vaccination hesitancy for COVID-19 vaccines: implications for health disparities	4
The effectiveness and value of aducanumab for Alzheimer’s disease	4
Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis	4
Impact of a human papillomavirus vaccination clinical program in a commercially insured population	4
Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma	4
Comparing and validating medication complexity from insurance claims against electronic health records	4
An observational analysis of disease burden in patients with cold agglutinin disease: Results from a large US electronic health record database	4
Need for payer-provider partnerships in addressing social determinants of health	4
Implementation of an adherence pharmacy referral protocol for patients taking sacubitril/valsartan	4
The evolution of payer management of oncology drugs in the United States between 2017 and 2022	4
Direct health care costs associated with COVID-19 in the United States	4
Real-world adherence and persistence with anaplastic lymphoma kinase inhibitors in non–small cell lung cancer	4
Social needs of dual-enrolled Medicare-Medicaid patients with medication nonadherence in a telehealth medication therapy management program	4
Drugs likely subject to Medicare negotiation, 2026-2028	4
Benefits of dapagliflozin in chronic kidney disease for US commercial payers: A cost-offset analysis	4
Persistence and other treatment patterns among bio-experienced patients with Crohn’s disease initiated on ustekinumab or adalimumab	4
Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis	4
Cost avoidance from health system specialty pharmacist interventions in patients with multiple sclerosis	4
Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States	4
Striving for affordable medicine: Lessons in price negotiation learned from the United Kingdom	4
Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies	4
Shifting paradigms: Reframing coverage of antiobesity medications for plan sponsors	4
Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model	3
A summit on amplifying voices of patients, caregivers, and people with disabilities in Inflation Reduction Act drug price negotiations	3
Descriptive study of the economic burden among patients with type 2 diabetes mellitus, chronic kidney disease, and chronic kidney disease and type 2 diabetes mellitus in a large US commercially insure	3
Corrections	3
Within-trial economic analysis of resource use from COMET-ICE: A phase 3 clinical trial evaluating sotrovimab for the treatment of patients with COVID-19 at high risk of progression	3
Comparison of oral anticoagulation use and adherence among Medicare beneficiaries enrolled in stand-alone prescription drug plans vs Medicare Advantage prescription drug plans	3
Individual and social determinants of adherence to sodium-glucose cotransporter 2 inhibitor therapy: A trajectory analysis	3
Trends in Medicaid spending on inhalers in the United States, 2012-2018	3
The effects of patient out-of-pocket costs for insulin on medication adherence and health care utilization in patients with commercial insurance; 2007-2018	3
Adverse event costs associated with first-line therapy for advanced non–small cell lung cancer in the United States: An analysis of clinical trials of immune checkpoint inhibitors	3
Poster Abstracts - Academy of Managed Care Pharmacy 2024	3
Limited utility of price transparency data for drugs	3
Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States	3
The potential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic TRK fusion thyroid cancer, colorectal cancer, and soft tissue sarcoma	3
Pharmacist impact on evidence-based prescribing of diabetes medications in patients with clinical atherosclerotic cardiovascular disease	3
Economic burden of interstitial lung disease in a commercially insured population with Sjögren syndrome in the United States	3
Real-world evidence: A new era is upon us	3
Time duration and health care resource use during cancer diagnoses in the United States: A large claims database analysis	3
Prompt initiation of triple therapy following hospitalization for a chronic obstructive pulmonary disease exacerbation in the United States: An analysis of the PRIMUS study	3
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations	3
Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies	3
Incorporating health equity into value assessment: frameworks, promising alternatives, and future directions	3
Increased delay from initial concern to diagnosis of autism spectrum disorder and associated health care resource utilization and cost among children aged younger than 6 years in the United States	3
The economic burden of HIV-associated wasting in the era of modern antiretroviral therapy	3
Performance-based pharmacy payment models: key components and critical implementation considerations for successful uptake and integration	3
The direct and indirect costs of adult atopic dermatitis	3
Economic outcomes of antiobesity medication use among adults in the United States: A retrospective cohort study	3
Risk of chemotherapy-induced febrile neutropenia in intermediate-risk regimens: Clinical and economic outcomes of granulocyte colony-stimulating factor prophylaxis	3
Factors associated with medication nonadherence among Medicare low-income subsidy beneficiaries with diabetes, hypertension, and/or heart failure	3
“It’s Time to Represent”: shifting the paradigm to improve the quality of inputs into value assessment frameworks	3
Budget impact of oral nirmatrelvir/ritonavir in adults at high risk for progression to severe COVID-19 in the United States	3
Web-based patient portal use and medication overlap from VA and private-sector pharmacies among older veterans	3
Prevalence of obesity-related multimorbidity and its health care costs among adults in the United States	3
Using latent class and quantum models to value equity in health care: a tale of 2 stories	3
Proposal for capturing patient experience through extended value frameworks of health technologies	3
Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol	3
DISCARDED MEDICATIONS IN VIALS ARE A SYMPTOM OF OUR HEALTH CARE SYSTEM: A CALL TO ACTION	3
Cost-effectiveness analysis of monthly, 3-monthly, and 6-monthly long-acting injectable and oral paliperidone in adults with schizophrenia	3
Underprescribing vs underfilling to oral anticoagulation: An analysis of linked medical record and claims data for a nationwide sample of patients with atrial fibrillation	3
Budget impact of lasmiditan for the acute treatment of migraine in the United States	3
Low rates of primary medication nonadherence in patients prescribed oral oncology agents across health system specialty pharmacies	3
Ensuring a high-quality and resilient supply chain of essential medications means paying more	3
Economic burden of invasive Escherichia coli disease among older adult patients treated in hospitals in the United States	3
Incremental health care expenditures for non-Hodgkin lymphoma in comparison with other cancers: Analysis of national survey data	3
THE AUTHORS RESPOND	3
The role of managed care pharmacy in coprescribing naloxone for patients with specific risk: recommendations from the AMCP Addiction Advisory Group	3
Payer perceptions of the use of real-world evidence in oncology-based decision making	3
Tirzepatide 10 and 15 mg vs semaglutide 2.0 mg: A long-term cost-effectiveness analysis in patients with type 2 diabetes in the United States	2
The cost impact of disease progression to metastatic castration-sensitive prostate cancer	2
Treatment patterns and hospitalizations following rejection, reversal, or payment of the initial once-monthly paliperidone palmitate long-acting injectable antipsychotic claim among patients with schi	2
Navigating the landscape of food allergies: Insights and perspectives from the AMCP Market Insights Program	2
Pharmacoequity measurement framework: A tool to reduce health disparities	2
Associations between pharmacy choice and influenza vaccination: Mail order vs community pharmacy users	2

Determining health care cost drivers in older Hodgkin lymphoma survivors using interpretable machine learning methods	2
Schizophrenia population health management: perspectives of and lessons learned from population health decision makers	2
Best practices in designing preapproval information engagements for US health care decision makers	2
Annual costs among patients with major depressive disorder and the impact of key clinical events	2
Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy	2
Impact of pharmacist alternative therapy interventions in a pediatric Medicaid population	2
Real-world treatment patterns, health care resource utilization, and costs in a US Medicare population with bronchiectasis	2
Economic burden and antidepressant treatment patterns among patients with major depressive disorder in the United States	2
The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with RET alterations	2
The effectiveness and value of gene therapy for hemophilia: A Summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum	2
Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects	2
Utilization and patient characteristics for the trastuzumab reference and biosimilars, and other human epidermal growth factor receptor 2 inhibitors in the United States	2
Xanomeline-Trospium in schizophrenia: A detailed review and comparison with the Institute for Clinical and Economic Review’s analysis	2
Incorporating health equity into value assessment: frameworks, promising alternatives, and future directions	2
Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis	2
Antidepressant therapeutic strategies and health care utilization in patients with depression	2
Geographic atrophy and factors associated with disease progression among Medicare Advantage enrollees	2
Relationship between social determinants of health and hospitalizations and costs among patients with bipolar disorder 1	2
Characterizing health plan evidence review practices	2
Considerations for US coverage and reimbursement: Which digital health products to evaluate? Findings from a modified Delphi study	2
Comorbid depression and anxiety and their association with health care resource utilization among individuals with type 1 diabetes in the United States	2
Understanding racial disparities in health care expenditures for cervical cancer	2
Real-world primary nonadherence to antiobesity medications	2
Cost-benefit analysis with return on investment of clinical pharmacists in the Military Health System	2
Health care costs and resource use of managing hemophilia A: A targeted literature review	2
Understanding the evolution of coverage policies for prophylaxis treatments of hemophilia A without inhibitors: a payer Delphi panel	2
A primer on copay accumulators, copay maximizers, and alternative funding programs	2
AMCP Partnership Forum: Patient input and payer decision-making	2
Outcomes of the use of infliximab biosimilars in rheumatology and gastroenterology clinics	2
COMMENT ON MODEL INPUTS AND ASSUMPTIONS FOR THE COST-MINIMIZATION MODEL USED TO COMPARE COST OF BIOLOGICS IN SEVERE ASTHMA	2
Association between adherence with oral anticancer medications and short-term health care resource utilization: A 2010-2018 claims-based analysis	2
A comparison of clinical, utilization, and cost outcomes between oral treatments for multiple sclerosis	2
Using continuous glucose monitoring to measure and improve quality metrics: Updates on the Healthcare Effectiveness Data and Information Set 2024 Glucose Management Indicator measure	2
Health insurance coverage and switching among people with hemophilia A in the United States	2
Perceptions of prior authorization by use of electronic prior authorization software: A survey of providers in the United States	2
Emerging trends in therapeutics and diagnostics: Perspectives on the 2024 AMCP Foundation Survey	2
The effectiveness and value of belimumab and voclosporin for lupus nephritis	2
Impact of a diabetes remote monitoring program on medication adherence	2
Incremental cost burden among patients with severe uncontrolled asthma in the United States	2
Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit	2
Analysis of a panel-based pharmacogenomics testing program among members of a commercial and Medicare client of a pharmacy benefits manager	2
Prescription drug coverage satisfaction, cost-reducing behavior, and medication nonadherence among Medicare beneficiaries with type 2 diabetes	2
Stakeholder perception of pharmaceutical value: A multicriteria decision analysis pilot case study for value assessment in the United States	2
Emerging trends in managed care pharmacy: A mixed-method study	2
Estimating the economic impact of blister-packaging on medication adherence and health care costs for a Medicare Advantage health plan	2
Cost-effectiveness of direct-acting antivirals for chronic hepatitis C virus in the United States from a payer perspective	2
Chronic graft-vs-host disease: Current understanding of disease and treatment landscape	2
The time is now: Addressing health inequities in the workforce	2
Correction	2
The effectiveness and value of sotatercept for pulmonary arterial hypertension: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Counci	2
Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective	2
Effect of listing strategies on utilization of antitumor necrosis factor biologics infliximab and etanercept: a cross-sectional analysis from Ontario, Canada	2
Budget impact of aripiprazole once every 2 months long-acting injectable for adult patients with schizophrenia in the United States	2
Economic and clinical outcomes of pegfilgrastim via prefilled syringe vs on-body injector: a real-world data analysis	2
The role of integrated medical and prescription drug plans in addressing racial and ethnic disparities in medication adherence	2
Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate	2
Evaluating patient-reported adherence and outcomes in specialty disease states: A dual-site initiative	2
Predictors of flare-related inpatient or emergency department stay in systemic lupus erythematosus: A real-world analysis of Medicaid claims in the United States	2
Assessing health care resource use, outcomes, and costs among Medicaid beneficiaries receiving factor IX prophylaxis for hemophilia B	2
The potential role of real-world evidence in Centers for Medicare & Medicaid Services’ future price negotiations: Recommendations for a robust framework	2
Antifibrotic therapies reduce mortality and hospitalization among Medicare beneficiaries with idiopathic pulmonary fibrosis	2
Association between health system specialty pharmacy use and health care costs among national sample of Medicare Advantage beneficiaries	2
The effectiveness and value of bempedoic acid and inclisiran for heterozygous familial hypercholesterolemia and secondary prevention of ASCVD	2
Cost-effectiveness of gilteritinib for relapsed/refractory FLT3mut+ acute myeloid leukemia	2
Medicare formulary restrictions for glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors used in type 2 diabetes mellitus: 2019-2023	2
Using latent class and quantum models to value equity in health care: a tale of 2 stories	1
Economic burden of recurrent hyperkalemia in patients with chronic kidney disease	1
Impact of discontinuing disease-modifying therapies on health care utilization among midlife patients with multiple sclerosis in the United States	1
The effectiveness and value of betibeglogene autotemcel for the management of transfusion-dependent beta-thalassemia	1
Assessment of racial and ethnic inequities in copay card utilization and enrollment in copay adjustment programs	1
Payer approval and rejection of oral anticoagulant prescriptions and prescription abandonment patterns among patients with venous thromboembolism	1
Reasons for switching oral antipsychotic medications and related patterns of care and costs in patients with schizophrenia initiating monotherapy treatment: Claims-linked chart study	1
Cheaper is not always better: Drug shortages in the United States and a value-based solution to alleviate them	1
Cost-effectiveness of eculizumab and efgartigimod for the treatment of anti–acetylcholine receptor antibody–positive generalized myasthenia gravis	1
Clinical and economic evaluation of tralokinumab for atopic dermatitis	1
Impact of a pharmaceutical care incentive program on the asthma medication ratio among pediatric patients with persistent asthma enrolled in a Medicaid program	1
Dose escalation of biologics in biologic-naive patients with Crohn’s disease: Outcomes from the ODESSA-CD study	1
Cost-effectiveness and budget impact of dolutegravir/lamivudine for treatment of human immunodeficiency virus (HIV-1) infection in the United States	1
Gene therapies for sickle cell disease: Effectiveness and value	1
The high cost burden of third- to fifth-line treatments for multiple myeloma: unsustainable and unaffordable	1
Antidepressant adherence using group-based trajectory modeling among postpartum women with Texas Medicaid	1
Introducing the Managed Care Pharmacy Primer Series	1
Real-world clinical and economic outcomes for patients with advanced non–small cell lung cancer enrolled in a clinical trial following comprehensive genomic profiling via liquid biopsy	1
Clinical characteristics and treatment patterns of patients with NTRK fusion–positive solid tumors: A multisite cohort study at US academic cancer centers	1
Limited role of patient input in specialty drug coverage policies	1
Trends in add-on medications following metformin monotherapy for type 2 diabetes	1
Association between multiple sclerosis disease severity and adherence to disease-modifying therapies	1
Underutilization or appropriate care? Assessing adjuvant chemotherapy use and survival in 3 heterogenous subpopulations with stage II/III colorectal cancer within a large integrated health system	1
The impact of capping health system cost savings on the projected cost-effectiveness of etranacogene dezaparvovec compared with factor IX prophylaxis for the treatment of hemophilia B	1
Social determinants of health and adult influenza vaccination: a nationwide claims analysis	1
Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States	1
Patient out-of-pocket and payer costs for pegfilgrastim originator vs biosimilars as primary prophylaxis of febrile neutropenia in the first cycle among a commercially insured population	1
Medicare Part D low-income subsidies expanded in January 2024, but more needs to be done to ensure that eligible beneficiaries enroll	1
Projecting long-term clinical outcomes with larotrectinib compared with immune checkpoint inhibitors in metastatic nonsmall cell lung cancer and differentiated thyroid cancer	1
Association of health care utilization and costs with patient-reported outcomes in patients with ankylosing spondylitis	1